Not exact matches
«It is anticipated that this
novel compound will have significant efficacy in human melanomas and other cancers either as a stand - alone
therapy or in
combination with other targeted or immune - based
therapies,» explained co-corresponding author Rhoda Alani, MD, the Herbert Mescon Chair of Dermatology at Boston University School of Medicine (BUSM).
«Researchers identify
novel mechanism in
combination drug
therapy for acute myeloid leukemia, other cancers.»
Researchers at The University of Texas MD Anderson Cancer Center developed a
novel chimeric mouse model to test the
combination therapy using immune checkpoint blockades with
therapies targeting myeloid - derived suppressor cells (MDSCs).
The study, «Non-toxic metabolic management of metastatic cancer in VM mice:
novel combination of ketogenic diet, ketone supplementation, and hyperbaric oxygen
therapy,» was published online today in PLOS ONE.
A team of researchers from the Hyperbaric Biomedical Research Laboratory at the University of South Florida (USF) doubled survival time in an aggressive metastatic cancer model using a
novel combination of non-toxic dietary and hyperbaric oxygen
therapies.
These
therapies could enhance the effects of
novel cancer immunotherapies when used in
combination, resulting in better health outcomes for cancer patients.
«This
novel combination therapy simultaneously targets multiple pathways contributing to metastasis» explains Professor Augustin, «On the one hand, we inhibit the growth of new blood vessels in metastases.
Based on these surprising therapeutic effects, the scientists initiated experiments aimed at unraveling the underlying molecular mechanisms of the
novel combination therapy.
The second branch of the
combination therapy, the low - dose metronomic chemotherapy, was similarly found to exert its therapeutic effect through a
novel, hitherto unrecognized mechanism: The metronomic chemotherapy turned out to not primarily target the tumor cells, but to act on the recruitment of yet another tumor - promoting cell population from the bone marrow.
The
novel drug
combination allows the rapidly emerging cancer
therapies called immune checkpoint inhibitors to be incorporated into a transplant patient's cancer treatment regimen.
New studies from the Abramson Cancer Center of the University of Pennsylvania are providing fresh clues on potentially effective
combinations with CAR T
therapy in brain cancer as well as a
novel therapeutic target in head and neck cancer, and also providing greater understanding of the mechanisms of resistance in pancreatic cancer.
As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell
therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some
novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.
To address the challenges of treating TBI and stroke, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have developed and patented a
novel approach combining three distinct classes of drugs to create a multi-drug
combination therapy.
A Multi-arm, Phase Ib, Open - Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in
Combination with Ascending Doses of
Novel Therapeutics in Patients with EGFRm + Advanced NSCLC who have progressed following
therapy with an EGFR TKI (TATTON)
A U.S. biotech company will attempt to resurrect 20 brain - dead patients by a
combination of
novel therapies involving brain stem cells.
World Advanced
Therapies and Regenerative Medicine Congress Speaker: Mark Zimmerman, Ph.D., Vice President, Operations and Business Development Presentation: New data on a
novel stem cell
combination product for diabetes — development and clinical update Date / Time: May 17, 3:30 PM BST Location: Business Design Centre, London
These
therapies are now being tested in various type of cancer and
novel combination approaches are being developed at a very fast pace.
He is using this knowledge to help design
novel drugs and
combination therapies to fight TB.
However, for the majority targeted
therapies in development — and their
combinations with current standard
therapies — there are still no approved diagnostic tools to determine which patients are most likely to benefit from or be resistant to these
novel agents or drug
combinations.
My research efforts are focused on identifying
novel combination therapies for breast cancer and the mechanisms that lead to drug resistance.
The approach is to use clinically relevant tumor models such as patient - derived xenografts (PDXs), as well as humanized and immunocompetent transgenic tumor - bearing mice to design rational
combinations of
novel and emerging cancer
therapies, including tumor - targeting and immune - stimulating
therapies, to ultimately improve treatment outcomes for cancer patients.
Phase 1b study of a
novel immunotherapy
combination therapy of intralesional Coxsackievirus A21 and systemic ipilimumab in patients with advanced melanoma.
* Expertise in developing
novel combination therapies, identifying drug resistance mechanisms, signaling pathways, tumor microenvironment.